Midori Ishii on Muck Rack

Midori Ishii

United Kingdom
As seen in: University of Oxford, Wiley Online Library, Frontiers, Cell Press, Cell Reports Medicine, medRxiv
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Midori

Contact Midori, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Dual-antigen recognition iPSC-derived CAR-T cells for B-cell malignancies: establishment of a COVID-19 vaccine synergy strategy

|
By Yoshiki Furukawa, Shintaro Kinoshita, Midori Ishii, Ayaka Goto, Hajime Yasuda, Jun Ando, Hiromitsu Nakauchi, Miki Ando, Norihide Izumi
| Frontiers
Abstract Introduction: CD19-directed chimeric antigen receptor (CD19-CAR) T-cell therapy has markedly improved outcomes in relapsed and refractory B-cell malignancies, but its efficacy remains limited by insufficient in vivo persistence and functional exhaustion.
Open in Who Shared Issue with article?

Immune recovery in tumor microenvironment of TP53-mutated AML following venetoclax combination therapy

|
By Kohei Yamada, Jun Ando, Yoshiki Furukawa, Midori Ishii
| medRxiv
J.A. received research grant and honoraria from AbbVie. Y.E. received research funding from AbbVie. T.T. received research funding from Bristol Myers Squibb and Sysmex. M.A. received research funding from Century Therapeutics and Daiichi-Sankyo and received research grants from Sumitomo Pharma, Chugai Pharmaceutical, Kyowa Kirin, AbbVie, Shionogi, Eisai, and Daiichi Sankyo. J.A. received research grant and honoraria from AbbVie. Y.E. received research funding from AbbVie.
Open in Who Shared View Duplicates (9) Issue with article?

Generation of iPSC-derived CD4+ Th1 cells enhancing chimeric antigen receptor-T cell cytotoxicity

|
By Yoshiki Furukawa, Midori Ishii, Shintaro Kinoshita, Ayaka Goto
| biorxiv.org
Abstract CD4+ T cells are anticipated to enhance the overall immune response, including the anti-tumor activity of chimeric antigen receptor (CAR)-T cell therapy. In the past, we established a culture system to generate CD8+ T cells from iPS cells (iPSCs); however, it was challenging to generate CD4+ T cells.
Open in Who Shared Issue with article?
See all 11 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified